MWNA
MXCT icon

Marshall Wace North America’s MaxCyte MXCT Stock Holding History

Marshall Wace North America’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$128K Buy
+10,511
New +$158K ﹤0.01% 1355

Other funds holding MXCT

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
DCP
D1 Capital Partners New York $34.8B AUM 11.34% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MAM
Montanaro Asset Management London, United Kingdom $317M AUM 16.08% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
RGI
River Global Investors London, United Kingdom $515M AUM 24.86% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Marshall Wace North America's MXCT Position: Q3 2021 in Review

Marshall Wace North America opened a new position in MaxCyte (MXCT) in Q3 2021: 10,511 shares worth $128K. The stake represents ﹤0.01% of the portfolio and ranks #1355 among its holdings.

80 funds tracked by Wall St. Rank hold MXCT as of Q3 2021.

  • Marshall Wace North America held 10,511 shares of MaxCyte worth $128K as of Q3 2021.
  • MaxCyte was a new Marshall Wace North America position in Q3 2021.
  • MaxCyte made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1355 holding.
  • 80 funds tracked by Wall St. Rank held MaxCyte as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.